Novartis to buy U.S. biotech firm Avidity Biosciences for about $12 billion in cash

by | Oct 27, 2025 | news, Top News

Novartis will pay Avidity shareholders $72 a share in cash, a premium of 46% to the company’s Friday closing price.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments